Science Corporation and Neurosoft Bioelectronics announced today that they partnered to bring neural recording tools to a brain-computer interface (BCI) platform.
The partnership brings Science’s full stack of clinical-grade neural recording tools from the Science BCI Ecosystem to Neurosoft, which develops ultra-soft interfaces aimed at achieving full-cortical coverage powering a foundational AI model of the brain.
According to a news release, Science Ecosystem partners enter into multi-year BCI development agreements. They utilize the full neural stack from the company, founded by Max Hodak, who also co-founded Elon Musk’s BCI venture, Neuralink.
Neurosoft aims to leverage advanced soft materials engineering and AI to restore motor and speech functions in people with severe neurological disorders with its BCI. It already reports more a dozen human implants for its system. Now, leveraging the Science Ecosystem, it can eliminate costs and complexities associated with custom hardware development.
According to a news release, it can cost between $75 million and $100 million to build a full-stack, clinical-grade BCI. This partnership enables first-in-human trials that cost less than $5 million, thanks to access to Science’s BCI technology.
More about the existing Science and Neurosoft technologies
Science Corp. looks to progress its first product, the Prima BCI retinal implant. It acquired the Prima technology developed by Pixium Vision in 2024.
The Prima System, a photovoltaic substitute of photoreceptors, already has FDA breakthrough device designation. It provides simultaneous use of the central prosthetic and peripheral natural vision.
Prima restores vision by directly activating the retina if rods and cones have been lost. It features a small light-powered implant placed under the retina and a special pair of glasses. The glasses have an embedded camera and infrared projector that sends light signals to the implant to provide power and data.
Science submitted Prima for commercial availability in the U.S. and Europe in June. As it looks to bring the system to market, it launched a patient registry in September 2025, then reported positive data in October 2025.
Neurosoft Bioelectronics develops what it considers to be the next generation of soft implantable electrodes to interface with the brain for the treatment of severe neurological disorders. The Switzerland-based company’s technology utilizes techniques that engineer elasticity in thin metal films of sub-micron thickness.
Commentary from Science and Neurosoft officials
Max Hodak, CEO and Founder of Science, said:
“We recognize that neural engineering breakthroughs happen at the intersection of diverse expertise. By providing robust, modular building blocks designed to meet the requirements of the most rigorous modern BCI applications, we are enabling innovation leaders across the BCI industry to develop targeted therapeutic solutions without rebuilding fundamental infrastructure, ultimately bringing transformative therapies to patients faster.”
Nicolas Vachicouras, PhD, CEO & Co-Founder of Neurosoft, said:
“This partnership with Science is a strategic move that aggressively accelerates clinical adoption, bringing potentially life-changing therapies to patients faster than ever seen before in the industry, while rapidly scaling the high-fidelity neural data collection essential for powering Neurosoft’s foundation AI models.”
Darius Shahida, chief strategy officer at Science, said:
“Neurosoft is the ideal partner to debut this model. “This partnership reflects Science’s broader vision to foster a community of BCI innovators working toward life-changing therapies for neurological injury and disease, and to advance the field by reducing development cost and complexity. Our multiyear, multimillion-dollar agreement is a significant milestone. I fully expect it will be the first of many.”